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Abstract
Background aims. Multipotent mesenchymal stromal cells (MSCs) are distinguished by their ability to differentiate into a
number of stromal derivatives of interest for regenerative medicine, but they also have immunoregulatory properties that are
being tested in a number of clinical settings.Methods.We show that brief incubations with rapamycin, everolimus, FK506 or
cyclosporine A increase the immunosuppressive potency of MSCs and other cell types. Results. The treated MSCs are up to
5-fold more potent at inhibiting the induced proliferation of T lymphocytes in vitro. We show that this effect probably is due
to adsorption of the drug by the MSCs during pre-treatment, with subsequent diffusion into co-cultures at concentrations
sufﬁcient to inhibit T-cell proliferation. MSCs contain measurable amounts of rapamycin after a 15-min exposure, and the
potentiating effect is blocked by a neutralizing antibody to the drug. With the use of a pre-clinical model of acute graft-versus-
host disease, we demonstrate that a low dose of rapamycin-treated but not untreated umbilical cordederived MSCs
signiﬁcantly inhibit the onset of disease. Conclusions. The use of treated MSCs may achieve clinical end points not reached
with untreated MSCs and allow for infusion of fewer cells to reduce costs and minimize potential side effects.
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Introduction
Mesenchymal stromal cells (MSCs) are deﬁned by
their ability to differentiate into osteoblasts, chon-
drocytes and adipocytes [1], but much of the cur-
rent clinical interest is aimed at exploiting their
immunoregulatory properties [2,3]. A prevailing
hypothesis is that MSCs exert their beneﬁcial ef-
fects on tissue regeneration, not through replace-
ment of damaged cells, but by providing anti-
inﬂammatory signals and growth factors that pro-
mote the regeneration process [4]. MSCs have been
shown to actively suppress the function or differ-
entiation of all immune cell types tested (mono-
cytes, dendritic cells, B and T lymphocytes and
natural killer cells), and multiple mechanisms
appear to be involved, including cell-cell contact
and secretion of agents such as prostaglandins,
transforming growth factor, indoleamine oxidase,
TSG6, or heme oxygenase [4e7].
Hundreds of clinical trials have been registered
that involve infusion of autologous, second-party or
third-party MSCs derived from bone marrow, adi-
pose tissue or umbilical cord (Clinicaltrials.gov).
Many of the applications are directed at inhibition of
undesirable immune responses such as acute graft-
versus-host disease (aGVHD) after hematopoietic
stem cell transplantation, rejection of solid-organ
transplants or autoimmune diseases such as multi-
ple sclerosis and Crohn’s disease [8,9]. Current
protocols use relatively small numbers of MSCs per
treatment, on the order of 1  106/kg body weight
[10,11]. It is surprising that positive responses have
been reported from such low doses, particularly
because tracking experiments indicate that MSCs
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act in a transient manner, and few are detected even
several days after infusion [12]. The ability of
intravenously injected MSCs to localize at sites of
tissue damage is one mechanism by which such
limited cell numbers could promote repair [13],
and the release of exosomes with immunoregula-
tory potential could allow for disseminated effects
[14]. Although the properties of MSCs make them
attractive for treating inﬂammatory conditions, they
can also be co-opted by tumors, in which their
trophic and immunosuppressive functions could
promote disease [15].
There is interest in exploiting the homing ability
of MSCs to use them as drug delivery systems and, to
this end, they have been genetically modiﬁed to
produce cytokines and enzymes for anti-cancer pro-
drug conversion [16e18]. Although MSCs are not
thought to persist long after infusion, any genetic
manipulation introduces the potential for oncogenic
or other undesirable changes and complicates their
clinical application. In the current report, we
describe a method by which the immunoregulatory
potency of MSCs, as well as other cell types, can be
increased without genetic modiﬁcation simply by
brief exposure to immunosuppressive drugs (ISDs).
The ability to combine the homing and suppressive
activities of MSCs with ISDs has the potential to
increase the therapeutic potential of this experi-
mental cell therapy and to reduce production costs if
fewer MSCs are required per treatment.
Methods
MSCs and ﬁbroblasts
Umbilical cord MSCs (UC-MSCs) were generated
as described [19] from fresh cord segments collected
from full-term births by NHS Cord Blood Bank
(NHS-CBB) staff (Colindale, United Kingdom) af-
ter informed ethical consent was obtained. Cells
were cultured at 37C with 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (DMEM):F12 (Lonza)
with penicillin/streptomycin (Sigma) and 10% fetal
calf serum (FCS) (Life Technologies) and were
passaged with the use of 0.125 % trypsin (Sigma).
Bone marrow (BM)-MSCs were generated through
the use of standard methods from frozen aliquots of
mononuclear cells (MNCs) purchased from DV Bi-
ologics. Brieﬂy, the MNCs were thawed and plated
in a tissue culture ﬂask with the medium as above.
After colonies of MSC-like cells were observed, they
were passaged, and expanded and their phenotype
was assessed by means of ﬂow cytometry for the
presence and absence of surface markers (cluster of
differentiation [CD]73, CD90, CD45 and CD34;
Biolegend) as described [19].
The HS27 human foreskin ﬁbroblast cell line
(ECACC) and primary human dermal ﬁbroblasts
(TCS Cellworks) were grown under the conditions
used for MSCs. Human umbilical vein endothelial
cells (HUVECs) were purchased from ECACC and
Life Technologies and expanded in endothelial cell
growth medium (TCS Cellworks).
Mononuclear cells
Adult peripheral blood (AB) MNCs from consenting
platelet donors were prepared from apheresis cones
[20] provided by NHSBT. The contents of the cones
were diluted with calcium and magnesium-free
phosphate-buffered saline (PBS) and were centri-
fuged over Lymphoprep (Axis-Shield); cells at the
interphase were then subjected to a 200g, 12-min spin
to deplete platelets. Aliquots were frozen in 10%
dimethyl sulfoxide (DMSO), 20% FCS and 70%
DMEM:F12 and stored in a 150 freezer (Pana-
sonic). Puriﬁed CD4þ responder T-cell populations
were prepared by means of incubation of MNCs with
biotinylated antibodies against CD8, CD14, CD15,
CD16, CD19, CD56 and HLA-DR (Biolegend);
depletion with streptavidin-coated magnetic beads
(Sigma) was then performed. CD4þ populations
were depleted of T-regulatory cells (Tregs) with the
use of magnetic beads to remove CD25þ cells (Mil-
tenyi Biotec), with the efﬁciency tested by means of
staining for CD25 and CD127, and for FoxP3 after
perm/ﬁx treatment (eBioscience) and incubation with
PE-labeled anti-FoxP3 (eBioscience clone PCH101)
(Supplementary Figure 1). Antigen-presenting cells
(APC) were generated through magnetic bead
depletion of MNCs with biotinylated anti-CD2 and
anti-CD3 and used in a 1:1 ratio withCD4þT cells as
described [21]. For cell proliferation assays, MNCs
and lymphocytes were labeled with carboxy-
ﬂuorescein succinimidyl ester (CFSE) (Sigma) as
described [21].
Drug treatment and suppression assays
Rapamycin was purchased as a 2.5 mg/mL DMSO
solution; cyclosporine A (CsA), everolimus, azathio-
prine, mycophenolate mofetil and FK-506 mono-
hydrate (all from Sigma) were dissolved in DMSO,
with aliquots stored at 20 until use. For drug pre-
treatment of MSCs and ﬁbroblasts, cells were
cultured in T25 ﬂasks with 5 mL of standard growth
medium until near conﬂuence. Drug stock solutions
were diluted in DMSO such that they were added to
the cultures at 10 mL. These volumes of DMSO
were shown to have no effect on MSC function in
control experiments (data not shown). At times
indicated in the text, the medium was removed from
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the cells, which were then rinsed with 5 mL of PBS.
Trypsin was added in a 1-mL ﬁnal volume (0.125%)
at room temperature until cells detached; cells were
then neutralized with 250 mL of FCS and diluted with
5 mL of PBS before centrifugation. After complete
aspiration of the supernatant and a second PBS wash,
the cell pellet was resuspended in growth medium at
an initial concentration of 2.5  105 cells/mL, with
two further 5-fold dilutions made in medium to
distribute 1000, 5000 and 25,000 cells/well in 100-mL
aliquots to U-bottomed 96-well plates (BD Falcon).
Where noted, some treatments were carried out on
trypsinized cells in suspension in 5 mL of standard
growth medium with 50 ng/mL of the indicated drug.
Control co-culture wells were prepared with 100 mL
of growth medium alone. After 2 to 4 h was allowed
for cell adhesion, CFSE-labeled responder lympho-
cytes (MNCs or CD4) were resuspended at 5  105
cells/mL MSC growth medium and 100-mL aliquots
distributed to the MSC and control plates. Where
indicated in the text, T-cell activation was induced
with phytohemagglutinin-L (Sigma) at 0.5 mg/mL
ﬁnal concentration, T-cell activation beads (Miltenyi)
at 1 bead/2 MNCs or 1:1 co-cultures of CD4 T cells
and allogeneic APC (5  104 cells each).
Cell proliferation was monitored with the use of
CFSE dye dilution after 3 to 4 days of culture with
phytohemagglutinin (PHA) or activation beads or 6
days for allostimulation, with 3 to 4 wells for each
condition pooled and the cells stained with antibodies
to CD3 (PerCP), CD25 (Pe-Cy7) and CD4 (APC-
Cy7) (Biolegend) for analysis on a FacsCanto II
(Becton Dickinson). Inﬁnicyt cytometry software was
used to determine the cell numbers in each division
cohort. Proliferation indices (PI) were calculated in
Excel (Microsoft) by use of the formula: (P0 þ P1 þ
P2 þ.)/(P0 þ 0.5 P1 þ 0.25 P2 þ.), where P0 is
the number of cells undivided, P1 is one division
and so forth. To normalize samples for compari-
son, the PI of samples stimulated in the absence of
MSC (PI stim) were deﬁned as 1 and unstimulated
controls (PI unstim) were 0: PI norm¼ [(PI n PI unstim)/
(PI stim PI unstim)].MNCs from at least three different
donors were used for each experiment, and Student’s t-
tests were performed in Excel for determining
signiﬁcance.
Washout experiments
UC-MSCs were treated with 100 or 500 ng/mL of
rapamycin in six-well plates with 2.5 mL of medium
per well. After 2 h, the medium was removed from all
wells, which were then rinsed several times with PBS.
One set of wells was trypsinized and the MSCs were
plated as above for suppression assays. The remain-
ing wells were prepared with 2.5 mL of fresh growth
medium without drug and returned to the incubator
for 24 h of further culture; cells were then trypsinized
and plated for suppression assays with the use of
aliquots of frozen MNCs from the same donors as
used on the previous day.
Drug neutralization
UC-MSCs at near conﬂuence in T25 ﬂasks in stan-
dard growth medium were treated for 75 min with 50
ng/mL of rapamycin; cells were then distributed to
96-well plates as described above for suppression
assays. Fifteen minutes before addition of CFSE-
labeled reporter MNCs, dilutions of a sheep anti-
rapamycin immunoglobulin (Ig) fraction or a pre-
immune control (Aalto Bio Reagents) were added
to the MSC-containing wells or to control wells
previously prepared to provide a ﬁnal concentration
of 0.5 or 2.5 ng/mL rapamycin (200 mL, ﬁnal vol-
ume). The “1” condition corresponded to 2 mg/mL
of immune immunoglobulin (0.4 mg/well), which,
in prior experiments, was sufﬁcient to neutralize
the anti-proliferative effect of 0.5 ng of rapamycin
in the standard 200-mL suppression assay volume
(Supplementary Figure 2). T-cell stimulation was
performed with the use of PHA, and proliferation
was monitored as above.
Rapamycin measurements
Triplicate cultures of UC-MSCs in T25 ﬂasks were
decanted, and 5 mL of fresh standard growth me-
dium or medium containing 50 ng/mL of rapamycin
was added. After 15 min at 37, the medium was
removed and stored in two aliquots at 80. The
cultures were rinsed with 5 mL of PBS; the cells were
then detached in 1 mL of trypsin (0.125%). The
suspension (1.2  106 cells) was distributed equally
between two conical tubes, and each was made up to
15 mL with 100 mL of FCS and PBS. The tubes were
centrifuged to pellet the cells, and all supernatant
was aspirated off. The cells were resuspended in 500
mL DMEM:F12 without FCS and stored at 80.
One of each pair of aliquots was used to determine
that the levels of rapamycin were within the dynamic
range for the rapamycin assay. Brieﬂy, 150-mL sam-
ples were mixed with 450 mL of methanol:zinc sul-
phate extraction reagent containing an internal
standard, desmethoxyrapamycin (Pﬁzer), and quan-
tiﬁed by means of mass spectrometry.
Humanized mouse model of aGVHD
Male and female BALB/c RAG2/common gamma
chain (gc)/mice (Charles River) between 8 and 15
weeks oldwere used for an aGVHDxenogeneicmodel
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[modiﬁed from those described by Ali et al. [22] and
Moncrieffe et al. [23]]. Mice were maintained under
pathogen-free conditions at the Biological Science
Unit Animal Facility King’s College London. All an-
imal experiments were speciﬁcally approved by the
Institutional Committees on Animal Welfare of the
United Kingdom Home Ofﬁce (the Home Ofﬁce
Animals Scientiﬁc Procedures Act, 1986).
Xenogeneic aGVHD was induced by the intra-
venous injection of adult human MNCs prepared as
above: 1.5  107 MNCs in 200 mL of PBS or 200 mL
of PBS alone (ie, no aGVHD control) were injected
through the tail vein 24 h after total body irradiation
at 400 cGy. At day 9 after irradiation, mice given
human MNCs were intravenously injected with
0.5  106 or 2  106 UC-MSCs; 0.5  106 UC-
MSCs pre-treated for 16 h with 100 ng/mL of
rapamycin; or 1  50 ng or 3  50 mg rapamycin (ie,
50 mg injected on 3 consecutive days), all in 200 mL
of PBS. A control group of aGVHD mice was
injected with 200 mL of PBS alone. Animal weights
were measured and recorded every 2 to 3 days after
irradiation. Animals that developed clinical symp-
toms of severe aGVHD (>15% weight loss, hunched
posture, fur loss, reduced mobility, tachypnea) were
euthanized, and an end point of survival was recor-
ded for all mice. Surviving mice were euthanized at
the termination of the experiments. Experiments
were undertaken twice, and the results of the two
experiments were subsequently pooled together.
Survival analysis was performed with the use of
Prism (GraphPad), with a log-rank (Mantel-Cox)
test used for comparisons.
Tissue samples (spleen, lung, liver, gut and kid-
ney) were extracted for analysis at the time of
euthanasia. Approximately 0.5cm2 of sample from
each tissue was excised and passed through 50-mm
cell strainers (BD Falcon) to obtain single-cell sus-
pensions. Red blood cells (RBCs)were removed from
the cell suspensions with RBC lysis solution (eBio-
science). Approximately 0.5  106 cells were stained
with ﬂuorescently labeled mouse antibodies to hu-
man CD3, CD4, CD8 and CD45 (Biolegend) and
analyzed by means of ﬂow cytometry for their human
MNC content. All mice given human MNCs and
killed or surviving at day 69 after irradiation
had 8% of cells from at least one of their tissues
analyzed that were positive for human CD45.
Results
Pre-treatment of MSCs from different sources with
rapamycin increases their immunosuppressive potency
In a screen of modiﬁers of signaling pathways
potentially involved in MSC-monocyte interactions
[21], it was observed that pre-treatment of MSCs
with rapamycin for 24 to 48 h led to a dose-
dependent increase in their ability to inhibit T-cell
proliferation. The increased suppression was seen
with treated MSCs derived from bone marrow
(Figure 1A) or umbilical cord (Figure 1B), as
measured by proliferation of T lymphocytes in MNC
preparations stimulated with PHA. With a pre-
treatment of 50 ng/mL there was a consistent and
signiﬁcant inhibition even at the lowest ratio of
MSCs to MNCs (1:50). Incubation of MSCs with
higher doses of rapamycin (100, 500 ng/mL) did not
lead to substantial increases in the effect (data not
Figure 1. Rapamycin pre-treatment increases the immunosup-
pressive potency of MSCs. (A) BM-MSC cultures were incubated
for 24 h with 0 (control), 0.4, 2, 10 or 50 ng/mL rapamycin before
re-plating for co-culture at 1 k, 5 k and 25 k with 50 k PHA-
stimulated MNCs. The ratios of MSCs:MNCs are indicated.
“P” represents the proliferation index of CD3þ cells in the
absence of MSCs and is deﬁned as 1. Error bars in this and sub-
sequent ﬁgures represent standard deviation of the mean; asterisks
indicate P < 0.05 as compared with the same number of untreated
MSCs (n ¼ 6). The raw and normalized data for one experiment
are provided in Supplementary Figure 3. (B) Representative UC-
MSC line was used in a suppression assay as above with gating
performed on CD3þCD4þ T cells (n ¼ 3). (C) CD3þCD4þ
lymphocytes and parallel preparations depleted of CD25þ cells
(see Supplementary Figure 1) were stimulated with anti-CD3,
eCD28 beads in the presence of control MSCs or cells pre-
treated with rapamycin (n ¼ 6).
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shown), and 50 ng/mL was used for subsequent ex-
periments unless noted. Puriﬁed CD4þ T cells
stimulated with anti-CD3, anti-CD28 activation
beads were also inhibited to a greater degree by
rapamycinepre-treated MSCs, and the effect did not
require the presence of CD25þ Tregs (Figure 1C).
The relatively weaker inhibition of proliferation of
the puriﬁed CD4þ cells is consistent with our earlier
ﬁnding that monocytes are required for maximal
suppression by MSCs [21]. Enhanced suppression
was also seen with CD4þ T cells stimulated by
allogeneic APCs in the presence of rapamycin-
treated MSCs (data not shown).
Enhancement by rapamycin is rapid, transient and
additive to immunosuppression by MSCs
Initial experiments used 24- to 48-h pre-treatments
on the hypothesis that sustained inhibition of the
mTOR pathway in the MSCs might lead to a
strengthening or induction of immunosuppressive
mechanisms. However, time-course studies showed
that equivalent effects were achieved with in-
cubations as short as 5 min (Figure 2A). With such
brief exposures, the MSCs can be incubated with
drug while in suspension after trypsinization (data
not shown). MSCs could also be frozen after drug
treatment with retention of their enhanced suppres-
sive activity upon thawing (Supplementary Figure 4),
further simplifying their preparation for potential
clinical use.
To examine the persistence of the rapamycin ef-
fects, we performed wash-out experiments
(Figure 2B). When MSCs were treated, washed and
cultured for 24 h in fresh medium without drug, the
rapamycin effect was diminished but still signiﬁcant.
An increase to 500 ng/mL of rapamycin pre-
treatment did not prolong the drug’s effect (data
not shown). After several passages, the drug-treated
cells showed no increased suppressiveness as
compared with controls, but re-treatment restored
the effect (data not shown). Wash-out experiments
were also used to test the possible effects of rapa-
mycin exposure on the proliferation and differentia-
tion of MSCs. After 24-h treatment with levels of
rapamycin shown to increase suppressiveness
(50e100 ng/mL), subsequent rates of expansion or
adipogenic differentiation [19] were not inhibited
signiﬁcantly (data not shown).
Previous reports on the interactions between
ISDs and MSCs have suggested that the suppressive
effects of rapamycin on T-cell proliferation are
inhibited by the presence of MSCs [24]. We did not
ﬁnd signiﬁcant inhibition of rapamycin effects, but
there was a trend to a slightly less-than-additive effect
when T cells were activated in the presence of both
the drug and MSCs that had not been pre-treated
(Figure 2C). These results suggest that MSCs and
rapamycin act to inhibit T-cell proliferation through
largely independent mechanisms, and there is no
evidence for synergy or rapamycin-induced stimula-
tion of MSC-suppressive mechanisms.
Rapamycin is taken up by MSCs and the enhancement
effect is blocked by a neutralizing anti-serum
Rather than modifying the physiology of the MSCs
by inhibition of mTOR, another possibility is that
increased suppression of T-cell proliferation is due to
Figure 2. Time course of rapamycin effect. (A) Parallel cultures of
UC-MSCs were incubated with rapamycin at 50 ng/mL for 5, 20
or 60 min and used in suppression assays as above (n ¼ 8). (B)
Parallel cultures were treated with/without rapamycin at 100 ng/
mL for 2 h; one control/treated pair was used immediately to set
up a suppression assay (day 0, triangles), whereas a second pair
was washed and then cultured for a further 24 h in fresh medium
without drugs (day þ1, squares). Solid ﬁgures: control MSCs,
open ﬁgures: rapamycin-treated MSCs. MNC aliquots from the
same donors were used to monitor suppression for the two sets of
treated MSCs (n ¼ 6). *P < 0.05 as compared with the same
number of untreated MSCs. (C) Titration of rapamycin (0 to 12.5
ng/mL) was carried out in the absence (triangles) or presence
(open squares) of 1 k untreated MSCs (1:50 ratio to MNCs) to
assess their possible interactions in the inhibition of PHA-
stimulated CD4þ T-cell proliferation. Induced proliferation in
the absence of MSCs or drugs was assigned to be 1; the calculated
additive effect of MSCs and drugs is shown with circles (n ¼ 4).
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the action of rapamycin itself in the assay cultures.
We calculated that the trypsinization and washing
steps involved in re-plating the MSCs after drug
treatment would reduce any carry-over in the me-
dium to levels below that seen to inhibit T cells
(Figure 2C). However, the lipophilic nature of
rapamycin is known to result in signiﬁcant partition
into red and white blood cells in vivo [25]. Mass
spectrometry measurements showed that after a 15-
min incubation with 5 mL of medium containing
250 ng of rapamycin, an average of 79  28 ng (n ¼
3) was present in a pellet of 1.2  106 cells. There-
fore, transfer of 5000 treated cells into a 200-mL
suppression assay would deliver approximately 0.3
ng of rapamycin, resulting in a concentration (1.5 ng/
mL) sufﬁcient for signiﬁcant inhibition of T-cell
proliferation if it was available to diffuse from the
MSCs to the lymphocytes.
To test the possibility that the treated MSCs were
adsorbing the drug and introducing it into the sup-
pression assay cultures, neutralization experiments
were performed. In control experiments with MNC
cultures treated with rapamycin in the absence of
MSCs, a pre-determined “1” amount of antibody
was able to block the inhibition caused by 2.5 ng/mLof
drug in a 200-mL culture volume and did not affect
suppression by untreated MSCs (Supplementary
Figure 2). As seen in Figure 3, inclusion of an anti-
serum directed against rapamycin but not a pre-
immune control inhibited all of the drug-dependent
increase in suppressive activity. Together with detec-
tion of rapamycin in the MSCs, this indicates strongly
that the drug-induced increase in suppression is
mediated by the drug itself and that the rapamycin
effect is additive to the immunosuppression caused by
the native MSCs. Observations that MSCs inhibit
rapamycin’s effects on T-cell proliferation could
therefore be due to buffering of the drug by the MSCs
in co-cultures.
Other cell types are made more suppressive by rapamycin
If rapamycin is taken up by MSCs because of their
lipophilic nature, then pre-treatment of other cell
types might also make them more immunosuppres-
sive. Indeed, primary and permanent ﬁbroblastic
lines became more suppressive when pre-treated with
rapamycin (Figure 4A,B). Rapamycin also enhanced
the suppressiveness of mouse embryo ﬁbroblasts,
showing that the effect is not speciﬁc for human cells
(data not shown). HUVECs did not suppress T-cell
proliferation substantially except at the highest ratios
(1 HUVEC:2 MNCs), but treatment with rapamycin
made them signiﬁcantly suppressive even at 1:50
(Figure 4C). As seen with MSCs, the drug-
dependent increase in suppression was totally
blocked by anti-rapamycin (Figure 4C), indicating
that the enhanced effect was due primarily to
adsorption and release of the drug rather than to
induction of immune-inhibitory mechanisms in the
HUVECs.
Pre-treatment of dendritic cells for 24 h with
rapamycin has been reported to increase their tol-
erogenic function without inhibiting their migratory
ability [26]. In addition to the reported reduction in
co-stimulatory molecules caused by the drug, we
hypothesized that absorption and release of rapa-
mycin by APCs could also contribute to their
reduced activation of T cells. As shown in Figure 4D,
incubation of APCs with rapamycin signiﬁcantly re-
duces their allo-stimulatory function, and this
decrease is fully reversed by neutralization with anti-
rapamycin. Therefore, under our experimental con-
ditions, the effect of the drug itself on T-cell prolif-
eration appears to be the dominant mechanism of
suppression.
Other ISDs can increase the potency of MSCs
Several other ISDs were tested to determine if they
could also increase the immunosuppressive potency
of MSCs. As shown in Figure 5A, the rapalogue
everolimus increases the potency of MSCs with a
similar dose proﬁle as seen with rapamycin. FK506
(tacrolimus) binds to the same cellular target protein
(FKBP12) as does rapamycin but acts through a
different downstream mechanism [27]. Orange et al.
[28] have reported that FK506 is adsorbed rapidly
and then released by dendritic cells in a manner
analogous to our observations for rapamycin.
Figure 3. The increased suppression by pre-treated MSCs is
blocked by an anti-serum against rapamycin. T-cell proliferation
induced by PHA (¼1 without MSC) was measured in co-cultures
with 1 k, 5 k and 25 k untreated UC-MSCs (solid black line, di-
amonds) or those pre-treated for 75 min with 50 ng/mL rapamycin
(dotted black line, circles). Pre-immune serum (dashed blue lines,
triangles) or a 1 amount of anti-rapamycin (dash-dot red line,
squares) was added to the MSC cultures 15 min before addition of
50 k MNCs. When anti-rapamycin was added to reactions con-
taining rapamycin-treated MSCs, the resulting T-cell proliferation
was equivalent to that seen with control MSCs and signiﬁcantly
different from the treatedMSCs at 1:50 and 1:10 (*P< 0.05, n¼ 4).
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Indeed, FK506 also increased suppressiveness of
both MSCs (Figure 5A) and HUVECs in the 10- to
50-ng/mL range (Figure 5B). The action of FK506
was also rapid, allowing for treatment of cells in
suspension (Figure 5B). CsA did not show any effect
when used to pre-treat MSCs at 50 ng/mL (data not
shown), but therapeutic doses are substantially
higher than those for rapalogues and tacrolimus.
When MSCs were pre-treated at 5 mg/mL CsA, they
were signiﬁcantly more immunosuppressive than
were controls (Figure 5C).
Rapamycin-treated MSCs show increased potency in a
pre-clinical aGVHD model
Acute GVHD is a serious cause of morbidity and
mortality in patients receiving hematopoietic stem
cell transplants and has been one of the main appli-
cations for MSCs in clinical trials [9]. As a stringent
test of whether pre-treatment of MSCs improves
their potency in vivo, we tested a low dose (5  105)
of control UC-MSCetreated or rapamycin-treated
cells and a higher dose (2  106) of untreated cells
for their ability to inhibit the onset of aGVHD in a
xenogeneic model. The low dose of untreated UC-
MSCs showed no signiﬁcant beneﬁt, but, when
pre-treated with rapamycin, they were superior to the
higher dose as measured by survival or weight loss
(Figure 6A,B). Whereas the higher dose of MSCs
showed a trend toward promoting greater survival
(P ¼ 0.24), only the cohort receiving rapamycin-
treated cells showed a signiﬁcant survival advantage
over the non-treated xenogeneic group (P ¼ 0.03).
From our measurements of rapamycin taken up by
MSCs (see above) we estimated that 30 to 40 ng of
drug would be contained in 5  105 treated cells,
>1000 times less than therapeutic doses used by
others [29e31]. Indeed, even when animals were
treated with three doses of 50 mg of rapamycin, there
was no signiﬁcant inhibition of GVHD in our model,
indicating that there is a strong synergistic action
with MSCs pre-treated with drug. Analysis of tissues
showed that all animals induced for aGVHD con-
tained human CD45þ cells in all tissues tested,
conﬁrming that engraftment had occurred in all mice
and negating the possibility that some mice survived
because the infused human MNCs did not engraft.
The proportion of human MNCs in spleen was
Figure 4. Rapamycin pre-treatment of other cell types. (A) Hu-
man dermal ﬁbroblasts (n ¼ 5) and (B) the HS27 ﬁbroblastic cell
line (n ¼ 8) were pre-treated with rapamycin for 2 h at 10 ng/mL
and were then plated at 1, 5 and 25 k for suppression assays of
PHA-induced CD4þ T-cell proliferation as for MSCs. (C) Un-
treated HUVECs (control) or those pre-treated with rapamycin for
15 min at 50 ng/mL were plated for suppression assays with
(Rþanti-R) or without anti-rapamycin. In comparison with control
HUVECs, the treated cells were more suppressive than the
equivalent number of control cells (P < 0.05) at all ratios, but there
was no signiﬁcant difference (NS) when anti-rapamycin was added
to the co-cultures (n ¼ 3). (D) APC preparations from three adult
donors were incubated with or without rapamycin at 50 ng/mL for
1 h and were then extensively washed before co-culture in a mixed
lymphocyte reaction (MLR). Each CD4þ responder was set up
against autologous APCs (Auto) and each of the other two allo-
geneic APCs (Allo). Anti-rapamycin was included in one set of
rapamycin pre-treated APC reactions, as for previous neutralization
experiments (Rþ anti-R).Therelativeproliferationonallo-stimulation
was deﬁned as 1 to normalize responses. NS, non-signiﬁcant.
*P < 0.05 (n¼ 6, 3 responders 2 allo-stimulators).
1194 J. Girdlestone et al.
signiﬁcantly lower in the animals receiving
rapamycin-treated cells, but this difference was not
evident in other tissues such as liver (Figure 6C), gut,
lung and kidney (not shown).
Discussion
MSCs have intriguing immunosuppressive proper-
ties that make them promising candidates as an off-
the-shelf cell product for regenerative medicine and
for treatment of autoimmune diseases and immune
complications of stem cell and solid-organ trans-
plantation [8,9]. For these latter indications, rela-
tively low numbers of MSCs have been infused
under current protocols, but insufﬁcient dose-
escalation studies have been performed to know the
optimal dosage and schedule of treatments. Some of
the most promising clinical responses have been re-
ported in children, in whom higher doses per kilo-
gram are more easily achieved, but a regimen of eight
injections at 2  106/kg [11] would provide logistical
and ﬁnancial challenges for adult patients. Although
MSCs can be expanded readily and no serious
adverse events have been associated with their
administration, there are concerns regarding prob-
lems arising from extensive passaging [32].
In studying the mechanisms by which MSCs
mediate their immunosuppressive effects with a view
to enhance their activity [21], we observed that pre-
treatment with rapamycin signiﬁcantly increased
their ability to inhibit T-cell proliferation. Rapamycin
is the canonical inhibitor of the mTOR pathway that
integrates sensing of nutrient and growth factor sig-
nals to regulate cell metabolism and proliferation
[33]. Lymphocytes are particularly sensitive to the
anti-proliferative actions of rapamycin, although
other cell types can be inhibited at higher doses.
Although mTOR inhibition is likely to alter MSC
metabolism to some degree, subsequent experiments
indicated that the primary basis of the enhanced
suppression is the action of the drug itself in trans,
with the MSCs acting as a drug delivery system.
Figure 5. Pre-treatment of MSCs with other immunosuppressive drugs. (A) UC-MSC were pre-treated for 2 h with the indicated doses (10,
50 ng/mL) of everolimus, FK506 and rapamycin and were then plated with 50 k MNCs at the indicated ratios for suppression assays (n ¼ 3).
(B) HUVECs were treated for 15 min in suspension with 50 ng/mL FK506 and were then washed twice before plating for suppression assays
as above (n ¼ 5). (C) UC-MSCs were pre-treated for 1 h with CsA at 5 mg/mL and were then plated for assays as above (n ¼ 9). *P < 0.05
compared with the equivalent number of control cells.
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FK506 showed a similar potentiating effect despite
acting through a distinct pathway to rapamycin,
although it does bind to FKBP12, the same cellular
target as the rapalogues [34]. However, because CsA
binds to cyclophilin rather than to FKBP12 [27]
yet also increased the suppressive activities of
MSCs, the accumulated results are consistent with
the enhancement effect being due to the drugs rather
than to regulation of a speciﬁc signaling pathway
within the MSC. Not all ISDs were found to enhance
the suppressive activity of MSCs; there was no sig-
niﬁcant change when azathioprine or mycophenolate
Figure 6. Pre-treatment of UC-MSCs increases their ability to inhibit onset of aGVHD. (A) Control mice (no MNCs: solid black line,
diamonds, n ¼ 5) or groups that were injected with human MNCs with or without UC-MSCs (MNC alone: red squares, n ¼ 8; MNC þ
0.5  106 MSCs, light blue circles, n ¼ 6; MNCs þ 0.5  106 MSC pre-treated with rapamycin, dark blue circles, n ¼ 8; MNCs þ 2  106
MSCs, green triangles, n ¼ 6; 3  50 mg rapamycin, black diamonds dotted line, n ¼ 5) were followed for 60 days and monitored for survival
and (B) body weight. Only the group receiving low-dose treated MSCs showed a signiﬁcant increase in survival over the xenogeneic control
(Mantel-Cox P ¼ 0.03) and also showed signiﬁcantly less weight loss (*P < 0.05). (C) The percentage content of human CD45þ cells was
determined in multiple tissues at euthanasia or at the end of the experiment, and results for spleen (left) and liver (right) are presented for
groups receiving human MNCs without UC-MSCs (e; n ¼ 5), 2  106 untreated MSC (2; n ¼ 4) and 0.5  106 MSCs that were untreated
(0.5; n ¼ 4) or pre-treated with rapamycin (0.5-R; n ¼ 7). Error bars represent standard deviation; asterisk indicates statistical signiﬁcance
compared with “e” animals (P < 0.05).
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mofetil was used for pre-treatment at 5 mg/mL (data
not shown). It is not known whether the biophysical
characteristics or metabolism of these compounds
prevent their effectiveness in pre-treatment of MSCs.
There are precedents for the loading of cells with
hydrophobic drugs, with Pessina et al. [35] reporting
that sufﬁcient amounts of the anti-cancer drug
paclitaxel were adsorbed by MSCs in a 24-h incu-
bation to reduce tumor growth in vivo and Orange
et al. [28] ﬁnding that FK-506eloaded dendritic cells
could inhibit autoimmune arthritis. A rapid partition
of ISDs into cells would appear to explain our ob-
servations of increased suppression by brief pre-
treatments of MSCs, ﬁbroblasts, APCs and
HUVECs and may explain at least part of the
increased suppression reported for rapamycin-
treated endothelia and Tregs [30,36].
It is well documented that rapamycin partitions
into blood cells [25], and measurement of rapamycin
in our treated MSCs showed sufﬁcient levels of drug
even after extensive washing to inhibit T-cell prolif-
eration in co-culture. The ability of a neutralizing
anti-serum to block the enhanced suppression
induced by pre-treatment of MSCs is strong evi-
dence that diffusion of the drug into the co-culture is
responsible for their increased potency. It is difﬁcult
to exclude the possibility that MSCs require the
continuous presence of rapamycin acquired in their
pre-treatment to maintain an enhanced suppressive
activity. However, the ability to neutralize the effect
shows that rapamycin is available for binding by
antibody in the medium and therefore could also be
free to act on lymphocytes in the co-cultures.
Although it is conceivable that rapamycin and other
ISDs may be inducing immunosuppressive factors in
MSCs and all the other cell types tested, the lack of
synergism when rapamycin and MSCs are added at
the same time argues against this mechanism as a
signiﬁcant contribution to the enhanced suppression
[24]. Therefore, the simplest explanation supported
by the results is that the enhanced suppression is due
to uptake and release of the drugs by the cells.
Wash-out experiments indicated a half-life of
approximately 1 day for the rapamycin effect on
MSCs in vitro, which raised questions as to whether
it would persist long enough to have an impact in
therapeutic situations. In vivo tracking indicates the
MSCs themselves have a half-life on the order of a
few days [12]; therefore, it is possible that even a
transient boost to their immunosuppressive activity
might be sufﬁcient to produce signiﬁcant clinical
beneﬁts. This was effectively demonstrated by the
ability of a single low dose (0.5  106) of rapamycin-
treated UC-MSCs to signiﬁcantly inhibit the onset of
xenogeneic GVHD. The same number of untreated
cells had no apparent effect, and, even a dose of
2  106, similar to that used in other studies [37,38],
showed only a trend toward greater survival.
Whereas rapamycin alone has been used for pre-
vention of solid-organ transplant rejection and
aGVHD in mice transplant models [30,31], doses of
3  50 mg were insufﬁcient in our experiments, as
was a single dose of 50 ng that we calculate to be the
approximate amount of drug introduced by the pre-
treated MSC (data not shown). Therefore, whereas
the suppressive effects of MSCs and rapamycin were
seen to be additive in vitro, synergism is indicated by
the in vivo model. Synergism has also been reported
with systemic administration of much higher doses of
rapamycin (2 mg/kg per day) together with MSCs in
a heart transplant model [29]. We postulate that the
enhancement in our in vivo model is due to the
MSCs acting as delivery vectors, targeting the drug
as well as their own repertoire of immunosuppres-
sants to sites of inﬂammation where they have been
reported to localize [39]. Our GVHD protocol
involved only a single injection of UC-MSCs, and it
remains to be determined if multiple doses of cells
pre-treated with rapamycin, or other ISDs, would
further inhibit the mortality and weight loss seen in
the second month after initiation of aGVHD.
MSCs and rapamycin have both been reported to
increase the proportion of Tregs through direct or
indirect mechanisms [40,41]. Although we found
that Tregs were not required for the rapamycin effect
on MSCs in vitro and do not appear to be necessary
for suppression by MSCs of solid-organ graft rejec-
tion [42], further experiments are required to
determine their potential contribution to the
rapamycin-treated MSC effect in vivo. There was a
trend toward lower proportions of human MNCs in
animals receiving MSCs in our GVHD model, but
the decrease was not substantial, and it remains to be
determined whether the treated MSCs inhibit disease
through promotion of Tregs and/or anergy of effector
lymphocytes.
The method that we have reported here for
combining a promising cellular therapy with stan-
dardly used ISDs has the potential to increase
signiﬁcantly the clinical utility of MSCs. The results
of our pre-clinical GVHD model indicate that it may
be possible to reduce the number of cells that are
required for infusion into a patient, thereby reducing
the costs of production and risks from over-
expansion. The use of pre-treated cells may also
allow for achievement of clinical end points that are
not reached with standard dosing regimens.
Although enhanced MSCs are unlikely to eliminate
the need for systemic administration of drugs that
have undesirable side effects, they may contribute
signiﬁcantly to their reduced use through targeted
delivery. More broadly, the demonstration that all
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cell types tested appear to sequester hydrophobic
ISDs opens up interesting possibilities for pre-
treatment of cells and tissues before infusion or
transplantation to reduce inﬂammation and
immune-mediated rejection.
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